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SUMMARY – Peripheral facial weakness is a facial nerve damage that results in muscle we-
akness on one side of the face. It may be idiopathic (Bell’s palsy) or may have a detectable cause. 
Almost 80% of peripheral facial weakness cases are primary and the rest of them are secondary. The 
most frequent causes of secondary peripheral facial weakness are systemic viral infections, trauma, 
surgery, diabetes, local infections, tumor, immune disorders, drugs, degenerative diseases of the 
central nervous system, etc. The diagnosis relies upon the presence of typical signs and symptoms, 
blood chemistry tests, cerebrospinal fluid investigations, nerve conduction studies and neuroima-
ging methods (cerebral MRI, x-ray of the skull and mastoid). Treatment of secondary peripheral 
facial weakness is based on therapy for the underlying disorder, unlike the treatment of Bell’s palsy 
that is controversial due to the lack of large, randomized, controlled, prospective studies. There are 
some indications that steroids or antiviral agents are beneficial but there are also studies that show 
no beneficial effect. Additional treatments include eye protection, physiotherapy, acupuncture, bo-
tulinum toxin, or surgery. Bell’s palsy has a benign prognosis with complete recovery in about 80% 
of patients, 15% experience some mode of permanent nerve damage and severe consequences remain 
in 5% of patients.
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Introduction
Peripheral facial weakness is a facial nerve damage 
that results in muscle weakness on one side of the face. 
It may have a detectable cause (secondary) or may be 
idiopathic without cause or without an obvious cause 
(primary, Bell’s palsy)1. Secondary peripheral facial 
weakness can be caused by metabolic diseases (diabe-
tes, preeclampsia2,3), stroke, infections (both viral and 
bacterial, e.g., herpes simplex infection, varicella zoster 
infection, influenza viruses, borreliosis), autoimmune 
diseases4 (Miller Fisher syndrome, Guillain-Barré 
syndrome, sarcoidosis), surgery5, trauma, tumors6, 
drugs7, and other causes8. Bell’s palsy or idiopathic 
peripheral facial weakness may only be diagnosed 
by exclusion of detectable causes. Due to the lack of 
sufficiently powered studies, therapy of primary and 
secondary facial weakness is controversially discussed, 
particularly if the causes of a secondary facial weak-
ness coexist with Bell’s palsy or if multiple causes of a 
primary facial weakness coexist in case of a secondary 
facial nerve palsy8.
The incidence of Bell’s palsy is estimated to 20-25 
cases per 100,000 population annually1. Bell’s palsy 
arises more frequently in the spring and fall than in 
any other time of the year. Women and men are usu-
ally equally affected8. Definitely, the prevalence is in-
creased in pregnant women (43 cases per 100,000)8. 
The peak incidence occurs between the second and 
fourth decade (15-45 years)1,8. It occurs with equal 
frequency on the right and left side of the face. Si-
multaneous, bilateral facial weakness is extremely rare 
with a prevalence of 0.3%-2% of facial palsies9. 
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Etiology of Bell’s Palsy
The etiology of Bell’s palsy is unknown but viral 
infection, vascular ischemia, and autoimmune disease 
have been postulated as the possible pathomecha-
nisms1,8. Bell’s palsy disproportionally occurs in preg-
nant women, patients who have diabetes, influenza, 
cold, some other respiratory infection, or have under-
gone tooth root extraction. Some patients report ex-
posure to an air-condition outlet, or an open window 
before the attack10. Family manifestation has also been 
reported2,11. Increasing evidence implies that Bell’s palsy 
is caused by latent herpes viruses (herpes simplex, her-
pes zoster), being reactivated from cranial nerve gan-
glia12. Reactivation of these viruses presumably causes 
inflammation of the facial nerve11. Initially, inflamma-
tion of the nerve results in reversible neurapraxia, and 
ultimately in wallerian degeneration8,12. Virus infection 
with herpes simplex type 1 or herpes zoster may pre-
dominantly occur if the immune system is simultane-
ously compromised. Herpes viruses have been detected 
by polymerase chain reaction (PCR) within the facial 
nerve13. There are confusing results concerning the role 
of Borrelia burgdorferi in the occurrence of Bell’s palsy. 
Some studies found an increased prevalence of Borrelia 
antibodies among patients with Bell’s palsy, whereas 
others could not confirm these results8.
Secondary peripheral facial weakness is caused by a 
number of different causes. Although it is often difficult 
to decide if any of these causes is responsible for the clin-
ical picture, it is important to distinguish primary from 
the secondary form, which may have a significant influ-
ence on therapy and prognosis3. Among 180 patients, 
Bell’s palsy was associated with arterial hypertension 
in 12%, diabetes in 11%, pregnancy or puerperium in 
4% and neurocysticercosis in 1%3. In another study, fa-
cial weakness was most frequently associated with viral 
infections, borreliosis, or diabetes14. However, if Bell’s 
palsy occurs simultaneously with a disorder, which also 
may cause secondary peripheral facial weakness, this 
does not necessarily imply a causal relation.
Pathophysiology
The precise cause of Bell’s palsy is unknown. A theo-
ry proposes that swelling of the facial nerve trunk in the 
narrow confines of the facial canal leads to local com-
pressive ischemia, which in turn leads to further swell-
ing and edema. The result is local interruption of blood 
supply to the facial nerve and thus extension of the isch-
emic injury. This compression of facial nerve has been 
seen in magnetic resonance imaging (MRI) scans15.
Clinical Presentation
Bell’s palsy is acute palsy of the facial nerve that 
results in muscle weakness usually on one side of the 
face. The clinical picture may differ, depending on 
the location of the lesion of the facial nerve along its 
course to the muscles. Symptoms and signs may also 
differ because of the fact that the facial nerve carries 
not only motor fibers including fibers to the stapedius 
muscle but also supplies autonomic innervation of the 
lacrimal gland, submandibular gland, sensation to part 
of the ear, and taste to the anterior two thirds of the 
tongue via chorda tympani8,12. Thus, Bell’s palsy is di-
agnosed upon abrupt onset of impaired facial expres-
sion due to unilateral facial weakness of all facial nerve 
branches, dry eye, if saliva runs out of the mouth, the 
inability to close or wink the eye or close the mouth, to 
droop the brow or the corner of the mouth, numbness 
or pain around the ear, temple, mastoid, or angle of 
the mandible, an altered sense of taste, hypersensitiv-
ity to sounds, or decreased tearing16. Patients may also 
mention otalgia, aural fullness, or mild retroauricular 
pain, which may even precede the palsy8. Speech and 
eating may also be disturbed. Severe pain suggests 
herpes simplex or zoster infection and may precede 
vesicular eruption and progression to Ramsay Hunt 
syndrome, characterized by typical cutaneous vesicles 
and vesicles in the conchal bowl, soft palate, or tongue 
and by vestibulo-cochlear dysfunction8,12. In almost 
half of the herpes zoster infections, vesiculation not 
necessarily appears or may be delayed (zoster sine her-
pete). Sometimes, the only clinical indication of her-
pes zoster is dysesthesia before vesiculation (described 
as preherpetic neuralgia). It is important to consider 
zoster sine herpete, since it is thought to be the cause 
of Bell’s palsy in quite a number of cases12. 
Evaluation of the Severity of Peripheral Facial 
Weakness
To evaluate the severity of peripheral facial weak-
ness clinically, various scoring systems are available. 
The most widely applied is the House-Brackmann fa-
Acta Clin Croat,  Vol. 52,  No. 2,  2013 197
Vanja Bašić-Kes et al. Peripheral facial weakness (Bell’s palsy)
cial nerve grading system (HBS). The degree of facial 
nerve palsy can also be evaluated by the Yanagihara 
grading system17, the Sunnybrook scales, the Jadad 
score of methodological quality, scales on computed 
systems, and various other systems18. Most grading 
systems rely on the evaluation of resting symmetry, 
degree of voluntary excursion of the facial muscles, 
and the degree of synkinesis (involuntary movement 
accompanying a voluntary movement) triggered by 
specific voluntary movements8. Facial weakness can 
be categorized as incomplete (partial) or complete (if 
there is inability to voluntarily contract the facial mus-
cles, hyperacusis, or loss of taste)19. The progression of 
weakness may be additionally assessed by reviewing 
some old photos and comparing them with the actual 
status. The degree of nerve damage can also be evalu-
ated by nerve conduction studies of the facial nerve. 
Reduction of the compound muscle action potential 
refers to the axonal degeneration, whereas increase in 
latency suggests demyelination of the nerve20.
Diabetes and Peripheral Facial Weakness
There are indications that the facial nerve is sub-
clinically involved in 6% of the patients with diabetes. 
Facial nerve affection, however, is less frequent than 
limb nerve affection. In one study, the rate of diabetes 
was 10% among 38 outpatients with Bell’s palsy. This 
figure did not differ from the anticipated frequency 
of diabetes in the general population21, raising doubt 
whether diabetic mononeuropathy of the facial nerve 
really exists. Neither the severity of facial nerve de-
generation, as assessed by facial nerve conduction 
studies, nor the clinical outcome was significantly dif-
ferent between diabetic and nondiabetic patients in a 
prospective study on 37 patients with Bell’s palsy22. 
Diagnosis
The diagnosis of peripheral facial weakness is 
based on clinical presentation with weakness of all 
facial nerve branches, drooping of the brow, incom-
plete eyelid closure, impaired closure of the mouth, 
drooping of the corner of the mouth, dry eye, hypera-
cusis, and impaired taste or pain around the ear. If 
eye closure is incomplete, Bell’s phenomenon occurs 
(upward diversion of the bulb on attempted closure of 
the eyelid)8. Transcranial magnetic stimulation seems 
capable of localizing the site of the lesion within the 
fallopian channel23. Nerve conduction studies show-
ing prolonged distal latency and reduced compound 
muscle action potential may provide useful informa-
tion on the severity and nature of the lesion8, although 
more prospective studies are required to assess the va-
lidity of nerve conduction studies for the prognosis 
of facial nerve lesions. Assessment of the ear should 
include pneumatic otoscopy, tuning fork tests, oto-
microscopy, and audiometry. Additional tests may 
include electronystagmography, videonystagmogra-
phy, and videooculoscopy. The stapedius reflex may be 
reduced or absent8. PCRs are basically used to dem-
onstrate the presence of herpes viruses and antibody 
tests are necessary to demonstrate the presence of 
Borrelia burgdorferi. Cerebrospinal fluid investigations 
may show pleocytosis, increased or decreased glucose, 
increased protein, antibodies against Borrelia burgdor-
feri, or various viruses or virus DNA or RNA8. The 
main task of all investigations is to find or to exclude 
the cause of peripheral facial weakness.
Therapy
The main goals of treatment are to speed recovery, 
to make recovery more complete, to prevent corneal 
complications and other consequences, and if there 
is a viral infection, to inhibit viral replication12. Psy-
chological support is also very important. Therapy of 
secondary facial weakness aims to act upon the par-
ticular cause of the palsy. Patients with Bell’s palsy 
should be referred to a specialist and treatment should 
start as soon as possible12. Treatment may be divided 




 Although steroids are often used in Bell’s palsy, 
their efficacy in this indication has not been clearly 
shown. Most of the studies on steroids in Bell’s palsy 
have a small sample size and a retrospective, observa-
tional design; rely on chart reviews, and lack random-
ization, control group, or blinding. On the one hand, 
there are studies, which clearly showed a beneficial 
effect of steroids in the treatment of Bell’s palsy, but 
there also are studies, which did not8.
198 Acta Clin Croat,  Vol. 52,   No. 2,  2013
Vanja Bašić-Kes et al. Peripheral facial weakness (Bell’s palsy)
In one randomized, double-blind, placebo-con-
trolled, factorial study on 496 patients with Bell’s 
palsy, after 3 months 83% in the corticosteroid group 
recovered facial functions compared to 64% in the 
placebo group24. After 9 months of follow up, this 
proportion increased to 94% in the corticosteroid 
group and 82% in the placebo group. The conclusion 
was that treatment with steroids within 3 days after 
onset significantly improved the chance for complete 
recovery at 3 or 9 months24. In another study on 62 
patients with Bell’s palsy, high-dose intravenous pred-
nisone given together with vitamins within 72 hours 
after onset resulted in better outcome as compared 
with controls, who received only vitamins25. In a study 
on 71 patients with Bell’s palsy, the administration of 
intravenous high-dose hydrocortisone together with 
low molecular dextran resulted in better outcome and 
less side effects in HBS I-II patients as compared to 
patients who received prednisone alone26. In a study 
on 76 patients, simultaneous administration of meth-
ylprednisolone and acyclovir resulted in reversion of 
the deficits to HBS I or II in 92% of cases27. All pa-
tients in HBS grade I-II recovered completely. For pa-
tients in HBS grade IV, V, and VI, complete recovery 
after 1 year was observed in only 94%, 86% and 50%, 
respectively27. In a randomized study on 46 patients 
with Bell’s palsy, of whom 23 received acyclovir and 
prednisone and 23 prednisone alone, those receiving 
combination therapy had better outcome on the facial 
nerve function index, as compared to those who were 
on steroids alone27. If steroids were combined with 
valacyclovir, complete recovery was observed in 88% 
of 56 patients with Bell’s palsy, whereas complete re-
covery was observed in only 68% of the patients who 
did not receive any therapy at all. Most studies rec-
ommend steroids for moderate to severe Bell’s palsy 
within the first 72 hours after onset and for the one-
fifth of patients in whom the palsy progresses8. A side 
effect of steroids for Bell’s palsy is frequent temporary 
aggravation of pre-existing diabetes. This is the reason 
why patients with uncontrolled diabetes should receive 
corticosteroids only under close monitoring of blood 
glucose24. According to two Cochrane reviews, there 
is no benefit of steroids alone or in combination28,29. 
These reviews also admit that the available studies 
were insufficiently powered to detect treatment effect. 
From three randomized trials, one with steroids versus 
placebo, one with steroids and vitamins versus vita-
mins, and one with steroids without a placebo group, 
including a total of 117 patients, the authors conclude 
that more randomized trials with a larger number of 
patients are needed to determine if there is potential 
harm or benefit from using steroids in Bell’s palsy29. 
In a study on 56 patients with Bell’s palsy, steroids did 
not result in significant improvement of the lesions 3 
and 6 weeks after onset30. In a study on 221 patients 
with Bell’s palsy, valacyclovir and corticosteroids were 
significantly better than corticosteroids alone31.
2) Antiviral agents 
Antiviral agents for Bell’s palsy are rarely given. 
Two Cochrane reviews on 246 and 200 patients, 
including three28 and two randomized trials32 with 
acyclovir and steroids versus steroids alone, acyclovir 
versus steroids33, and valacyclovir with steroids versus 
steroids34 conclude that the results of all three trials 
were inconclusive with regard to short- or long-term 
benefit and that a large, multicenter, randomized, 
controlled, and blinded study with a minimum fol-
low up of 1year is required before definite recom-
mendation regarding the effect of acyclovir or vala-
cyclovir can be given8,34. At least there does not seem 
to be a difference between oral acyclovir and steroids 
versus intravenous acyclovir and steroids8,14. A study 
on 221 patients with Bell’s palsy treated with vala-
cyclovir and prednisolone within 7 days after onset 
showed better outcome for patients receiving com-
bination therapy than corticosteroids alone31. In a 
study on 247 patients receiving acyclovir, complete 
recovery was observed in 71% after 3 months and in 
85% after 9 months24. The authors found no benefit 
of acyclovir alone or additional benefit of acyclovir in 
combination with corticosteroids24. For patients with 
zoster sine herpete, however, acyclovir appears to be 
effective8,12.
3) Pentoxifylline 
The efficacy of pentoxifylline on the recovery of 
Bell’s palsy has only been tested together with other 
drugs, particularly steroids and low-molecular dex-
tran. Studies showed a beneficial effect of such a com-
bination therapy, but which of these drugs is the one 
actually responsible for the beneficial effect, is so far 
unknown35.
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Nonpharmacological treatment
1) Mime and physiotherapy
Only a few controlled trials on the effectiveness 
of physical therapy for facial palsies are available12. In 
a randomized trial on 50 patients with Bell’s palsy, 
mime therapy, including automassage, relaxation 
exercises, inhibition of synkinesis, coordination ex-
ercises, or emotional expression exercises, resulted 
in improvement of facial stiffness, lip motility, and 
the physical and social indices of the facial disability 
index36. Patients with remaining symptoms of Bell’s 
palsy appear to experience positive effects from phys-
iotherapy37 and biofeedback training38. In a controlled 
study on 24 patients with Bell’s palsy, neuromuscular 
retraining exercises showed an effect in improving fa-
cial movements39.
2) Acupuncture and moxibustion 
Acupuncture is safe therapy with a low risk of ad-
verse events in clinical practice40. It is one of the most 
commonly used treatments for Bell’s palsy in China. 
Although only limited experience has been reported 
with acupuncture for Bell’s palsy12, several studies 
provide increasing evidence for a beneficial effect of 
acupuncture and moxibustion as an adjunctive treat-
ment for Bell’s palsy41,42.
Local treatment
In the acute phase, local treatment is very impor-
tant because eye care is imperative in Bell’s palsy. The 
patient’s eye is at risk of drying, corneal abrasion, and 
corneal ulcers. 
1) Eye protection 
One of the greatest problems with Bell’s palsy is 
drying of the eye if the lid fissure remains open. Eye 
care should be focused on the protection of the cornea 
from dehydration, drying, or abrasions due to insuf-
ficient lid closure or tearing12. Eye ointment and wet-
ting is proposed during day and night supported by a 
watch-glass bandage during the day or night.
Poor outcome treatment measures 
1) Pulsatile electrical current (transcutaneous 
electrical stimulation)
In patients with poor outcome and chronic facial 
nerve damage, long-term electrical stimulation may 
be beneficial. In a study on 12 patients with chronic 
Bell’s palsy and 5 patients whose facial nerves had 
been surgically sacrificed with a mean latency between 
onset and electrotherapy of 3.7 years, stimulation of 
the most affected muscles at a submotor level for 6 
h per day during 6 months significantly reduced fa-
cial nerve latencies, the HBS, and collective scores of 
the 12 clinical impairment measures after 6 months. 
An improvement by 40%, 30%, or less than 10% was 
reported in 5, 4 and 8 patients, respectively. The ben-
eficial effect was explained by facilitation of re-inner-
vation through electrical stimulation43.
2) Transmastoid decompression
In one study with 58 patients with Bell’s palsy 
having denervation exceeding 95%, transmastoid de-
compression of the facial nerve resulted in significant 
improvement of the HBS and Yanagihara scores 60 
days after onset44. In a prospective, multicenter tri-
al on patients with a chance of long-term sequels of 
Bell’s palsy, as assessed by nerve conduction studies 
and electromyography, surgical decompression of the 
facial nerve through the middle cranial fossa expo-
sure, including the tympanic segment, geniculate 
ganglion, labyrinth segment, and meatal foramen, 
significantly improved the chances for normal or near-
normal return of facial nerve functions if surgery was 
carried out within 2 weeks after onset of total paraly-
sis45. Since middle fossa craniotomy carries the risk 
of bleeding, infection, seizures, deafness, leakage of 
cerebrospinal fluid, or facial nerve injury, this surgi-
cal approach cannot be routinely recommended for 
patients with acute Bell’s palsy12.
3) Gold weight implant
Implantation of gold into the upper eyelids of 16 
patients with lagophthalmos due to Bell’s palsy result-
ed in significant reduction of lagophthalmos and im-
proved corneal coverage of 100%. Owing to delayed 
closure time and disrupted tear film, irritation of the 
cornea and sclera may persist, so that some patients 
require ongoing topical treatment of the eye, which 
may compromise visual acuity46.
4) Facial nerve cable grafting
In a retrospective study on 27 patients undergoing 
facial nerve grafting between 1982 and 1997, those 
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who had the nerve grafted to a site distal to the meatal 
foramen had better outcome than those with an anas-
tomosis proximal to the meatal foramen47. Microneu-
rovascular free muscle transfer and cross-face nerve 
grafting are other therapeutic options. The latter in-
volves one of the nerves used for biting10. In a study 
on 29 patients who had undergone previous removal 
of cerebellopontine angle tumor, hypoglossal-facial 
nerve anastomosis resulted in significant improvement 
in all of them. A HBS of III or better was achieved in 
65 of the included patients5.
5) Subperiosteal facial suspension (face lifting)
In an observational study on five patients with a 
HBS III-V, face lifting resulted in marked improve-
ment in four of them48.
6) Botulinum toxin
Synkinesis and facial spasms, common features 
of partially recovered facial nerve palsies, can be ef-
fectively managed by subcutaneous or intramuscular 
injections of botulinum toxin. In a study on ten pa-
tients with synkinesis during a period of 7 years on an 
average, periorbital injections of botulinum toxin A 
resulted in marked subjective and objective improve-
ment in nine of them8,49.
Prognosis of Peripheral Facial Weakness
Peripheral facial weakness can improve up to 1 year 
later. Patients with incomplete weakness have better 
prognosis than those with complete facial weakness, 
and the younger is the patient, the better is the prog-
nosis8. In patients with incomplete facial weakness, up 
to 94% make full recovery12. Without treatment, the 
prognosis of complete Bell’s palsy is generally good, 
but 20%-30% of the patients are left with varying 
degrees of permanent disability11,34. About 80%-85% 
of the patients recover spontaneously and completely 
within 3 months, whereas 15%-20% experience some 
kind of permanent nerve damage8,11. About 5% may 
remain with severe consequences1,34. About 10% of 
the patients with Bell’s palsy experience one or more 
recurrences after a mean latency of 10 years50.
Long-term sequels of Bell’s palsy may be persist-
ing weakness, contractures, facial spasms, synkinesis, 
decreased tearing, crocodile tears, or psychosocial ef-
fects1. In patients who recover without treatment, ma-
jor improvement occurs within 3 weeks. A new wave 
of recovery of function starts 3 months after onset. If 
it does not occur within this time, then it is unlikely 
to be seen by 6 months.
Conclusion
Patients developing Bell’s palsy should be treated 
by a neurologist, ENT specialist, and ophthalmolo-
gist with the least possible latency after palsy onset. In 
all patients suspected to have secondary facial nerve 
palsy, diagnostic work-up for the presence or absence 
of the possible causes should be promptly initiated. If 
any of these causes is detected, it should be assessed 
whether there is causal relation between the palsy and 
the detected cause or not. Although a final decision 
on optimal therapy for acutely developing Bell’s palsy 
cannot be actually proposed, patients should be pro-
vided with all therapeutic measures to avoid second-
ary affection of the eyes if eyelid closure is insufficient 
or in case of impaired tearing.
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Sažetak
PERIFERNA LEZIJA SEDMOG MOžDANOG žIVCA (BELLOVA PAREZA)
V. Bašić-Kes, M. Cesarik, L. Zadro Matovina, Z. Madžar, I. Zavoreo  i V. Demarin
Periferna lezija facijalnog živca označava oštećenje VII. moždanog živca koje rezultira mišićnom slabošću jedne strane 
lica. Može biti idiopatska (Bellova paraliza) ili može imati jasan uzrok. Gotovo 80% perifernih lezija facijalnog živca su 
primarne, a ostale su sekundarne. Među najčešće uzroke sekundarne periferne lezije facijalnog živca ubrajaju se sistemske 
virusne infekcije, trauma, operacijski zahvati, šećerna bolest, lokalne infekcije, tumori, imuni poremećaji, droge, degenera-
tivne bolesti središnjega živčanog sustava itd. Dijagnoza se zasniva na tipičnoj kliničkoj slici, pretragama krvi, likvora, pro-
vodljivosti živaca i neuroslikovnim metodama (MRI mozga, rtg lubanje i mastoida). Liječenje sekundarne periferne lezije 
facijalnog živca zasniva se na liječenju primarnog uzroka, za razliku od liječenja idiopatske periferne pareze facijalnog živca 
koje je još uvijek predmet nedoumica. Pojedine studije ukazuju na mogući pozitivan učinak steroida i antivirusnih lijekova, 
dok druge studije ne ukazuju na pozitivan učinak ovog liječenja. Dodatno liječenje uključuje zaštitu oka, fizioterapiju, aku-
punkturu, injiciranje botulinum toksina ili operacijski zahvat. Bellova paraliza ima uglavnom dobru prognozu s čak 80% 
potpunih oporavaka; u 15% slučajeva zaostane blaže oštećenje živca, dok u 5% bolesnika ostaju teže trajne posljedice.
Ključne riječi: Bellova pareza – dijagnostika; Bellova pareza – terapija; Akupunktura
